Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 13,466 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Peer Mentoring; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 30 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypogonadism
Interventions: TSX-002; Drug
Lead sponsor: TesoRx Pharma, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Hyperglycemia, Insulin Dependent Diabetes
Interventions: Hemoglobin A1c, Observation Unit; Diagnostic Test · Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 21 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Emergencies, Diabetes Mellitus
Interventions: Statewide Planning and Research Cooperative System Database; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 120 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Peripheral Artery Disease, Diabetes Mellitus, Chronic Limb-Threatening Ischemia
Interventions: SPECT/CT perfusion imaging, PET/CT perfusion imaging; Diagnostic Test
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Gynecologic Oncological Pelvic/Abdominal Surgery
Interventions: atorvastatin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pancreatitis, Diabetes
Interventions: Sitagliptin, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 2 Diabetes
Interventions: Peer Education, Control; Behavioral
Lead sponsor: Scripps Whittier Diabetes Institute; Other
Eligibility: 21 Years to 75 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Diabetes Mellitus Type 2
Interventions: Internet Intervention, Control; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Not listed
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama

Conditions: Ovarian Cancer
Interventions: Shared Medical Decision Tool, Engaging Patients in Decision Making, Literacy Spanish Language; Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: PreDiabetes
Interventions: Modified EAET for prediabetes; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer
Interventions: CYH33; Drug
Lead sponsor: Haihe Biopharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: New Haven, Connecticut • Dallas, Texas • Houston, Texas

Conditions: Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: carboplatin, etoposide, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Temple University; Other
Eligibility: 15 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2001
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 40 Years to 89 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity, Gender, Problem of Aging
Interventions: Cardiopulmonary Exercise Stress Test, Climatic-Controlled Cardiopulmonary Exercise Stress Test, Body Composition Evaluation, Pre-Exercise Risk Assessment; Procedure
Lead sponsor: Freeman-Sheldon Research Group, Inc.; Other
Eligibility: 35 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1972
U.S. locations: 1
States / cities: Buckhannon, West Virginia

Conditions: Obesity, Type 2 Diabetes
Interventions: HEALTH[e]TEEN, HEALTH[e]TEEN + CST; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Growth Hormone Deficiency
Interventions: TV-1106, Recombinant human growth hormone; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 23 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Type 1 Diabetes
Interventions: LY900014, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia • West Des Moines, Iowa • Minneapolis, Minnesota

Conditions: Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions: Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo; Drug · Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 6 Years to 28 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Diabetes Mellitus Type 1, Diabetes Mellitus Type 2
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years and older
Enrollment: 356 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Thyroid Eye Disease
Interventions: Efgartigimod PH20 SC, Placebo PH20 SC; Combination Product · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 16
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: Placebo, Relamorelin; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 113
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 95 more

Conditions: Type 2 Diabetes
Interventions: icovamenib 100 mg, Placebo; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Canoga Park, California • Long Beach, California + 17 more

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: pyridoxine hydrochloride, Placebo, doxorubicin HCL liposome; Dietary Supplement · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 8
States / cities: Cleveland, Ohio

Search by objective public record fields.

Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control

Oral Testosterone for the Treatment of Hypogonadism

Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED

Geography of ED Use and Population Health

Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease

High-dose Periop Statins for Prevention of DVT

Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant

Randomized Trial of Peer Led Education-Project Dulce

Internet Intervention to Improve Rural Diabetes Care

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

Emotional Awareness and Expression Therapy for Prediabetes

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Pragmatic Impact of Proteomic Risk Stratification in Diabetes Mellitus

Work-Related Effects of Heat, Activity, and Fat in Middle Aged Men

Reducing Obesity and Type 2 Diabetes in High Risk Youth

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

Natural History of Autoimmune Diabetes and Its Complications

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer